ampelopsin has been researched along with Liver Diseases, Alcoholic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhatti, AA; Davies, DL; Folk, C; Kim, P; Liang, J; Moradian, R; Silva, J; Spatz, MH; Yu, X | 1 |
| Bi, Y; Chen, J; Fu, J; Liu, B; Wang, X; Xia, T; Zhu, R | 1 |
1 review(s) available for ampelopsin and Liver Diseases, Alcoholic
| Article | Year |
|---|---|
Molecular mechanisms and therapeutic implications of dihydromyricetin in liver disease.
Topics: Carcinoma, Hepatocellular; Flavonols; Humans; Liver Diseases; Liver Diseases, Alcoholic; Liver Failure, Acute; Liver Neoplasms; Liver Regeneration; Non-alcoholic Fatty Liver Disease; Protective Agents | 2021 |
1 other study(ies) available for ampelopsin and Liver Diseases, Alcoholic
| Article | Year |
|---|---|
Dihydromyricetin Protects the Liver via Changes in Lipid Metabolism and Enhanced Ethanol Metabolism.
Topics: Adenylate Kinase; Animals; Dietary Supplements; Enzyme Activation; Ethanol; Fatty Liver, Alcoholic; Flavonols; Hep G2 Cells; Humans; Lipid Metabolism; Liver; Liver Diseases, Alcoholic; Male; Mice; Mice, Inbred C57BL; Triglycerides | 2020 |